SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

TPG Group Holdings (SBS) Advisors, Inc.

(Last)

(First)

(Middle)

C/O TPG GLOBAL, LLC

301 COMMERCE STREET, SUITE 3300

(Street)

FORT WORTH

76102

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
07/16/2014

3. Issuer Name and Ticker or Trading Symbol
Roka BioScience, Inc. [ ROKA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Series B Common Stock	529	I	See Explanation of Responses⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series A Common Stock	⁽⁶⁾	⁽⁶⁾	Series B Common Stock	3,880	⁽⁶⁾	I	See Explanation of Responses⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾⁽⁶⁾
Series B Preferred Stock	⁽⁵⁾	⁽⁵⁾	Series A Common Stock	1,123,188	⁽⁵⁾	I	See Explanation of Responses⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾
Series C Preferred Stock	⁽⁵⁾	⁽⁵⁾	Series A Common Stock	365,056	⁽⁵⁾	I	See Explanation of Responses⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾
Series D Preferred Stock	⁽⁵⁾	⁽⁵⁾	Series A Common Stock	641,393	⁽⁵⁾	I	See Explanation of Responses⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾
Series E Preferred Stock	⁽⁵⁾	⁽⁵⁾	Series A Common Stock	505,236	⁽⁵⁾	I	See Explanation of Responses⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾

1. Name and Address of Reporting Person^*

TPG Group Holdings (SBS) Advisors, Inc.

(Last)

(First)

(Middle)

C/O TPG GLOBAL, LLC

301 COMMERCE STREET, SUITE 3300

(Street)

FORT WORTH

76102

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

BONDERMAN DAVID

(Last)

(First)

(Middle)

C/O TPG GLOBAL, LLC

301 COMMERCE STREET, SUITE 3300

(Street)

FORT WORTH

76102

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

COULTER JAMES G

(Last)

(First)

(Middle)

C/O TPG GLOBAL, LLC

301 COMMERCE STREET, SUITE 3300

(Street)

FORT WORTH

76102

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

Explanation of Responses:

1. David Bonderman and James G. Coulter are officers and sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. ("Group Advisors" and, together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of TPG Biotechnology GenPar III Advisors, LLC, which is the general partner of TPG Biotechnology GenPar III, L.P., which is the general partner of TPG Biotechnology Partners III, L.P. ("TPG Biotech III").

2. TPG Biotech III directly holds (i) 3,880 shares of Series A Common Stock (the "Series A Common") of Roka Bioscience, Inc. (the "Issuer"), (ii) 529 shares of Series B Common Stock (the "Series B Common") of the Issuer, (iii) 12,400,000 shares of Series B Preferred Stock (the "Series B Preferred") of the Issuer, (iv) 4,030,224 shares of Series C Preferred Stock (the "Series C Preferred") of the Issuer, (v) 6,844,627 shares of Series D Preferred Stock (the "Series D Preferred") of the Issuer and (vi) 5,577,814 shares of Series E Preferred Stock (the "Series E Preferred" and, together with the Series B Preferred, Series C Preferred and Series D Preferred, the "Preferred Stock") of the Issuer.

3. Because of the relationship between the Reporting Persons and TPG Biotech III, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Biotech III. Each of TPG Biotech III and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Biotech III's or such Reporting Person's pecuniary interest therein, if any.

4. Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

5. Pursuant to the Sixth Amended and Restated Certificate of Incorporation of the Issuer, as amended (the "Certificate of Incorporation"), the shares of Preferred Stock are convertible, at the option of the holder, at any time into shares of Series A Common at initial conversion rates equal, (i) in the case of the Series B Preferred, the Series C Preferred and the Series E Preferred, to one share of Series A Common per share of Preferred Stock and (ii) in the case of the Series D Preferred, at an initial conversion rate equal to approximately 1.03 shares of Series A Common per share of Series D Preferred. The initial conversion rates have been adjusted as a result of a 1-for-11.04 reverse stock split of the Series A Common.

6. Pursuant to the Certificate of Incorporation, the shares of Series A Common reported herein are convertible, at the option of the holder, at any time into shares of Series B Common at an initial conversion rate equal to one share of Series A Common per share of Series B Common.

Remarks:

(7) The Reporting Persons are jointly filing this Form 3 pursuant to Rule 16a-3(j) under the Exchange Act. (8) Ronald Cami is signing on behalf of both Messrs. Bonderman and Coulter pursuant to the authorization and designation letters dated July 1, 2013, which were previously filed with the Securities and Exchange Commission.

	/s/ Ronald Cami, Vice President, TPG Group Holdings (SBS) Advisors, Inc. (7)	07/16/2014
	/s/ Ronald Cami on behalf of David Bonderman (7)(8)	07/16/2014
	/s/ Ronald Cami on behalf of James G. Coulter (7)(8)	07/16/2014
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.